AMRX · Amneal Pharmaceuticals Inc
United States · RS rating 89 · As of 2026-11-03
| Price | 20.21 USD |
|---|---|
| 1-day change | -1.1% |
| RS rating (overall / 1M / 3M / 12M) | 89 / 54 / 81 / 92 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 58 / 78 / 62 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | +72.7% |
| Sales growth Q/Q | +3.8% |
| Distance from 52-week high | +6.0% |
| Market cap (USD) | $4.0B |